Metabonomic Profiles Discriminate Hepatocellular Carcinoma from Liver Cirrhosis by Ultraperformance Liquid Chromatography–Mass Spectrometry

Wang, Baohong; Chen, Deying; Chen, Yu; Hu, Zhenhua; Cao, Min; Xie, Qing; Chen, Yanfei; Xu, Jiali; Zheng, Shusen; Li, Lanjuan

doi:10.1021/pr2009252

Cited by 123 publications

(118 citation statements)

References 46 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…29,30 A UPLC-MS-based metabolomics approach has been used to characterize serum profiles from HCC, liver cirrhosis (LC), and healthy subjects, and the accuracy of UPLC-MS profiles and AFP levels were compared for their use in HCC diagnosis. 31 Thirteen potential biomarkers were identified that suggest there were significant disturbances of key metabolic pathways in HCC patients. Of note, glycochenodeoxycholic acid was suggested to be an important indicator for HCC diagnosis and disease prognosis.…”

Section: Biomarkers and Metabolomics Studies On Hccmentioning

confidence: 99%

Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

2013

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the commonest primary hepatic malignancy and the third most common cause of cancer-related death worldwide. Incidence remains highest in the developing world and is steadily increasing across the developed world. Current diagnostic modalities, of ultrasound and a-fetoprotein, are expensive and lack sensitivity in tumor detection. Because of its asymptomatic nature, HCC is usually diagnosed at late and advanced stages, for which there are no effective therapies. Thus, biomarkers for early detection and molecular targets for treating HCC are urgently needed. Emerging highthroughput metabolomics technologies have been widely applied, aiming at the discovery of candidate biomarkers for cancer staging, prediction of recurrence and prognosis, and treatment selection. Metabolic profiles, which are affected by many physiological and pathological processes, may provide further insight into the metabolic consequences of this severe liver disease. Small-molecule metabolites have an important role in biological systems and represent attractive candidates to understand HCC phenotypes. The power of metabolomics allows an unparalleled opportunity to query the molecular mechanisms of HCC. This technique-driven review aims to demystify the metabolomics pathway, while also illustrating the potential of this technique, with recent examples of its application in

show abstract

Section: Biomarkers and Metabolomics Studies On Hccmentioning

confidence: 99%

Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

2013

View full text Add to dashboard Cite

show abstract

“…Canavaninosuccinate was first identified as a metabolite that is significantly reduced in liver cirrhosis and increased in HCC. In addition, GCDCA was suggested to be an important indicator for HCC diagnosis and disease prognosis [32]. Chronic liver diseases including chronic hepatitis B and hepatic cirrhosis are the major risk factors for development of HCC.…”

Section: Hepatocarcinoma (Hcc) Liver Cirrhosis and Chronic Liver Dismentioning

confidence: 99%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

118

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oObjectives: Metabonomics is a powerful and promising analytic tool that allows assessment of global lowmolecular-weight metabolites in biological systems. It has a great potential for identifying useful biomarkers for early diagnosis, prognosis and assessment of therapeutic interventions in clinical practice. The aim of this review is to provide a brief summary of the recent advances in UPLC-based metabonomic approach for biomarker discovery in a variety of diseases, and to discuss their significance in clinical chemistry.Design and methods: All the available information on UPLC-based metabonomic applications for discovering biomarkers of diseases were collected via a library and electronic search (using Web of Science, Pubmed, ScienceDirect, Springer, Google Scholar, etc.).Results: Metabonomics has been used in clinical chemistry to identify and evaluate potential biomarkers and therapeutic targets in various diseases affecting the liver (hepatocarcinoma and liver cirrhosis), lung (lung cancer and pneumonia), gastrointestinal tract (colorectal cancer) and urogenital tract (prostate cancer, ovarian cancer and chronic kidney disease), as well as metabolic diseases (diabetes) and neuropsychiatric disorders (Alzheimer's disease and schizophrenia), etc.Conclusions: The information provided highlights the potential value of determination of endogenous lowmolecular-weight metabolites and the advantages and potential drawbacks of the application of UPLC-based metabonomics in clinical setting.

show abstract

“…Novel metabolic markers are therefore a promising supplement to classic biomarkers. The combination of metabolic markers and traditional protein-based markers will be a trend in future biomarker applications [101][102][103].…”

Section: Translational Research On Tumor Metabolic Markersmentioning

confidence: 99%

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Yin

2013

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Early detection is the most effective way to improve the clinical outcome of malignancies. Although some tumor markers are now widely used in the clinic, their sensitivity and specificity are still not satisfactory. Thus, there is an urgent requirement for the discovery of new tumor markers. By measuring holistic endogenous metabolites, metabolomics can be used for delineating metabolic networks and discovering metabolic markers. Chromatography-mass spectrometry is the most widely used tool for metabolomics and has shown great potential for biomarker screening. In this review, the authors summarize: recent advances in the protocols and methodologies of chromatography-mass spectrometry-based metabolomics in the discovery of tumor markers; recently identified tumor metabolic markers for primary liver cancer, gynecologic cancer and genitourinary cancer and their applications; and commonly encountered problems in the translational research of metabolic markers.

show abstract

Metabonomic Profiles Discriminate Hepatocellular Carcinoma from Liver Cirrhosis by Ultraperformance Liquid Chromatography–Mass Spectrometry

Cited by 123 publications

References 46 publications

Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Contact Info

Product

Resources

About